Phospho-SRF (S103) Antibody

What is SRF and what role does phosphorylation at S103 play in its function?

Serum Response Factor (SRF) is a transcription factor that binds to the serum response element (SRE), a short sequence of dyad symmetry located approximately 300 bp to the 5' of the transcription initiation site of certain genes (such as FOS). SRF functions together with MRTFA transcription coactivator to control expression of genes regulating the cytoskeleton during development, morphogenesis, and cell migration .

Phosphorylation of SRF at serine residue 103 (S103) significantly enhances its binding to SREs, thereby activating transcription of target genes . This post-translational modification serves as a molecular switch that modulates SRF activity in response to various cellular signals, particularly stress-induced pathways.

Which signaling pathways regulate SRF phosphorylation at S103?

SRF phosphorylation at S103 is regulated through several interconnected signaling cascades:

• The p38 MAPK pathway: Stress stimuli such as anisomycin and UV radiation activate p38, which then signals through MAPKAP kinases (MK2/3) to phosphorylate SRF at S103 .

• RSK3-PP2A signalosome: SRF S103 phosphorylation is bidirectionally regulated by RSK3 (p90 ribosomal S6 kinase type 3) and PP2A (protein phosphatase 2A) at signalosomes organized by the scaffold protein mAKAPβ (muscle A-kinase anchoring protein β) .

• Rho GTPase pathway: The SRF-MRTFA complex activity responds to Rho GTPase-induced changes in cellular globular actin (G-actin) concentration, coupling cytoskeletal gene expression to cytoskeletal dynamics .

This multi-layered regulation allows for precise control of SRF activity in different cellular contexts and in response to various stimuli.

What are the primary applications of Phospho-SRF (S103) antibodies in research?

Phospho-SRF (S103) antibodies have several critical research applications:

These applications enable researchers to investigate SRF phosphorylation status across various experimental conditions and disease states.

How does SRF phosphorylation at S103 contribute to cardiac hypertrophy?

SRF phosphorylation at S103 plays a critical role in modulating asymmetrical cardiac myocyte hypertrophy, functioning as an epigenomic switch that balances myocyte growth in width versus length. This has significant implications for cardiovascular disease progression .

In concentric hypertrophy (associated with pressure overload), increased SRF phosphorylation activates AP-1 (activator protein-1)-dependent enhancers that direct myocyte growth primarily in width. Conversely, in eccentric hypertrophy (associated with volume overload), reduced SRF phosphorylation drives preferential growth in length .

The regulation of this phosphorylation is mediated through a signalosome complex:

• RSK3 promotes SRF phosphorylation at S103

• PP2A dephosphorylates SRF at S103

• Both enzymes are anchored to the scaffold protein mAKAPβ

Research using adeno-associated virus (AAV)-mediated gene delivery in mice has demonstrated that:

• Inhibition of RSK3 signaling prevents concentric cardiac remodeling induced by pressure overload

• Inhibition of PP2A signaling prevents eccentric cardiac remodeling induced by myocardial infarction

• Both interventions improve cardiac function in their respective models

What is the relationship between MAPKAP kinases and SRF phosphorylation in stress-induced gene expression?

MAPKAP kinases (MK2/3) play a direct role in stress-induced gene expression through SRF phosphorylation. Studies using MK2/3-deficient cells have revealed several key findings:

• Stress-induced phosphorylation of SRF at S103 is significantly reduced in MK2/3-double-deficient cells .

• Induction of SRE-dependent reporter activity is impaired in MK2/3-deficient cells and can only be rescued by catalytically active MK2 .

• The p38α-MK2/3-SRF signaling axis represents a critical pathway for transcriptional activation of immediate early genes (IEGs) .

• This transcriptional regulation by MK2/3 likely cooperates with their established role in post-transcriptional gene expression during inflammation and stress response .

Microarray experiments identified 27 genes significantly downregulated in MK2/3-deficient cells, with serum response elements (SREs) found in the promoter regions of 26 of these genes, highlighting the widespread impact of this pathway on stress-responsive gene expression .

How can phospho-SRF cistrome analysis enhance our understanding of transcriptional regulation?

The phospho-SRF cistrome (genome-wide binding profile of phosphorylated SRF) provides crucial insights into how phosphorylation alters SRF's genomic binding patterns and transcriptional output. In rat ventricular adult myocytes, phospho-SRF cistrome analysis has revealed:

• Distinct binding patterns compared to total SRF, suggesting phosphorylation directs SRF to specific genomic loci.

• Preferential association with AP-1-dependent enhancers that control genes involved in myocyte growth in width during concentric hypertrophy .

• Changes in cistrome profile during different forms of cardiac hypertrophy (concentric vs. eccentric), revealing phosphorylation-dependent transcriptional programs.

To conduct reliable phospho-SRF cistrome analysis, researchers should:

• Validate antibody specificity for the phosphorylated form

• Use appropriate controls including non-phosphorylated SRF ChIP

• Combine with precision nuclear run-on sequencing (PRO-seq) to correlate binding with active transcription

• Analyze results in context with known SRF co-factors (like MRTFA)

What are the optimal storage conditions for maintaining Phospho-SRF (S103) antibody activity?

For maximum stability and retention of activity, Phospho-SRF (S103) antibodies should be stored according to these guidelines:

• Temperature: Store at -20°C or -80°C upon receipt .

• Formulation: The antibody is typically supplied in liquid form in PBS containing 50% glycerol, 0.5% BSA, and 0.02% sodium azide, which helps maintain stability during storage .

• Aliquoting: To prevent repeated freeze-thaw cycles that can degrade antibody quality, divide the stock solution into small aliquots before freezing .

• Avoid repeated freezing: As explicitly stated in product information, avoid repeated freeze-thaw cycles that can denature the antibody and reduce its effectiveness .

• Short-term storage: For antibodies in active use, store at 4°C for up to one month, but return to -20°C or -80°C for longer-term storage.

Following these storage recommendations will ensure optimal antibody performance in experimental applications.

What controls should be included when using Phospho-SRF (S103) antibodies in research?

Robust experimental design with appropriate controls is essential when working with phospho-specific antibodies:

• Positive controls:

  • Lysates from cells treated with anisomycin or UV radiation, which are known to induce SRF phosphorylation at S103

  • Recombinant phosphorylated SRF protein (if available)

• Negative controls:

  • Dephosphorylated samples (treated with phosphatases)

  • Samples from cells treated with p38 inhibitors like SB202190 or SB203580, which block the signaling pathway leading to SRF phosphorylation

  • SRF-deficient cells or SRF knockdown samples

• Specificity controls:

  • Blocking peptide competition assays using the phosphopeptide immunogen

  • Parallel detection with antibodies against total SRF to compare phosphorylated versus total protein levels

  • Use of an SRF S103A mutant (serine to alanine) that cannot be phosphorylated

• Technical controls:

  • Secondary antibody-only controls to assess background signal

  • Loading controls (β-actin, GAPDH) for western blot applications

  • Isotype control antibodies (rabbit IgG) for immunoprecipitation experiments

What sample preparation techniques maximize detection of phosphorylated SRF?

Optimal detection of phosphorylated SRF requires careful sample preparation to preserve phosphorylation status:

• Cell/tissue lysis:

  • Use phosphatase inhibitor cocktails in all buffers to prevent dephosphorylation

  • Include protease inhibitors to prevent protein degradation

  • Perform lysis at cold temperatures (4°C) to minimize enzymatic activity

• Stimulation protocols:

  • For maximal SRF phosphorylation, stimulate cells with anisomycin (25 ng/ml) or UV radiation

  • For p38 pathway-specific activation, use anisomycin with appropriate controls (SB203580 for p38α/β inhibition)

  • Time course experiments are recommended (30-60 minutes typically optimal for stress-induced phosphorylation)

• For immunohistochemistry:

  • Use fresh-frozen or properly fixed tissues (phospho-epitopes can be sensitive to fixation)

  • Optimize antigen retrieval methods for phospho-epitopes

  • Consider using signal amplification methods for low-abundance phosphoproteins

• For western blotting:

  • Use fresh samples whenever possible

  • Consider phospho-protein enrichment techniques for low-abundance targets

  • Use gradient gels for optimal separation of phosphorylated and non-phosphorylated forms

How can researchers validate the specificity of Phospho-SRF (S103) antibodies?

Validating antibody specificity is crucial for reliable phospho-SRF detection:

• Peptide competition assays:

  • Pre-incubate the antibody with excess phosphopeptide (the immunogen used to generate the antibody)

  • A specific antibody will show significantly reduced signal when pre-blocked with its cognate phosphopeptide

  • Use non-phosphorylated peptide as control to confirm phospho-specificity

• Genetic approaches:

  • Express wild-type SRF versus S103A mutant (cannot be phosphorylated) in cells

  • A specific phospho-antibody will detect wild-type but not the S103A mutant after appropriate stimulation

• Pharmacological validation:

  • Treat cells with p38 pathway inhibitors (SB203580) to block SRF phosphorylation

  • A specific antibody will show reduced signal in inhibitor-treated samples

  • Treatment with phosphatase inhibitors should enhance detection

• Cross-reactivity testing:

  • Test the antibody against recombinant phosphorylated and non-phosphorylated SRF

  • Evaluate potential cross-reactivity with similarly phosphorylated motifs in other proteins

• Multi-technique validation:

  • Confirm findings using complementary techniques (Western blot, IHC, ELISA)

  • Compare results with alternative phospho-SRF antibodies when available

How can Phospho-SRF (S103) antibodies be used to study cardiac disease models?

Phospho-SRF (S103) antibodies are valuable tools for investigating cardiac pathophysiology, particularly in hypertrophy and heart failure models:

• Animal models application:

  • Detection of altered SRF phosphorylation in pressure overload (transverse aortic constriction) versus volume overload (myocardial infarction) models

  • Assessment of therapeutic interventions targeting the RSK3-PP2A-SRF signaling axis

  • Longitudinal studies tracking SRF phosphorylation status during disease progression

• Human sample analysis:

  • Comparative studies of SRF phosphorylation in healthy versus diseased human heart tissues

  • Correlation of phospho-SRF levels with clinical parameters and outcomes

  • Identification of patient subgroups based on SRF phosphorylation profiles

• Intervention studies:

  • Using AAV-mediated gene delivery of mAKAPβ-derived RSK3 and PP2A anchoring disruptor peptides to modulate SRF phosphorylation in vivo

  • Testing candidate compounds that modulate SRF phosphorylation as potential therapeutics

  • Monitoring phospho-SRF as a biomarker for treatment response

• Mechanistic investigations:

  • ChIP-seq studies to identify phospho-SRF binding sites in healthy and diseased hearts

  • Correlation with transcriptome data to identify phospho-SRF-dependent gene expression programs

  • Investigation of phospho-SRF interactions with cardiac-specific cofactors

What are the recommended antibody dilutions for different experimental applications?

Optimal antibody dilutions vary by application and should be empirically determined for each experimental system:

When working with a new lot of antibody, performing a dilution series is recommended to determine the optimal concentration for your specific experimental conditions. The antibody is typically supplied at a concentration of 1 mg/ml , which serves as the starting point for dilution calculations.

How does Phospho-SRF (S103) detection complement other methods for studying transcriptional regulation?

Phospho-SRF (S103) detection provides unique insights when integrated with other transcriptional analysis techniques:

• Complementary to gene expression analysis:

  • While RNA-seq or microarray studies identify differentially expressed genes, phospho-SRF detection reveals potential regulatory mechanisms

  • Integration of phospho-SRF ChIP-seq with transcriptome data can identify direct phospho-SRF target genes

  • Temporal studies can reveal how phospho-SRF changes precede gene expression alterations

• Enhancement of promoter-reporter assays:

  • SRE-dependent reporter assays provide functional readouts that complement phospho-SRF detection

  • Mutational analysis of SRF binding sites coupled with phospho-SRF detection can reveal phosphorylation-dependent transcriptional mechanisms

  • Reporter constructs like pGL3-mEgr1-370 or SRE reporter cell lines can be used alongside phospho-SRF detection

• Integration with interactome studies:

  • Phospho-SRF detection can be combined with co-immunoprecipitation to identify phosphorylation-dependent protein interactions

  • Analysis of how phosphorylation affects SRF interactions with other transcription factors like Elk1

  • Investigation of how signalosome components (mAKAPβ, RSK3, PP2A) interact with phospho-SRF

• Multi-omics integration:

  • Correlation of phospho-SRF levels with phosphoproteomics data to identify coordinated signaling events

  • Integration with epigenomic data (histone modifications, chromatin accessibility) to understand phospho-SRF's role in chromatin remodeling

  • Systems biology approaches to model phospho-SRF as part of broader transcriptional networks

What are common issues when detecting Phospho-SRF (S103) and how can they be resolved?

Researchers may encounter several challenges when working with Phospho-SRF (S103) antibodies:

• Weak or no signal:

  • Ensure phosphorylation is induced (verify activation of p38 pathway)

  • Check for phosphatase activity in samples (add fresh phosphatase inhibitors)

  • Increase antibody concentration or incubation time

  • Try alternative detection methods with higher sensitivity

  • Verify sample preparation preserves phospho-epitopes

• High background:

  • Increase blocking time/concentration

  • Optimize antibody dilution

  • Use more stringent washing steps

  • Consider alternative blocking agents

  • Reduce secondary antibody concentration

• Non-specific bands in Western blot:

  • Verify optimal primary antibody dilution

  • Increase washing stringency

  • Perform peptide competition assay to identify specific bands

  • Use gradient gels for better separation

  • Consider using purified phospho-SRF as a positive control

• Variability between experiments:

  • Standardize stimulation protocols (time, concentration)

  • Use consistent sample preparation techniques

  • Include internal controls in each experiment

  • Prepare larger batches of buffers to maintain consistency

  • Consider using automated systems for washing and processing

How do different stress conditions affect SRF phosphorylation dynamics?

SRF phosphorylation at S103 responds differentially to various stress conditions, providing insights into stress-specific signaling cascades:

• Anisomycin stimulation:

  • Induces robust SRF phosphorylation at S103 through p38 MAPK pathway activation

  • Phosphorylation typically peaks at 30-60 minutes post-stimulation

  • Requires catalytically active MK2 for efficient phosphorylation

  • Can be blocked by the p38α/β inhibitor SB202190

• UV radiation:

  • Also triggers SRF phosphorylation at S103 through the stress-activated p38 pathway

  • May involve additional DNA damage response pathways

  • Phosphorylation kinetics may differ from chemical stressors

• PMA stimulation:

  • Activates the ERK pathway rather than p38

  • Does not significantly affect SRF S103 phosphorylation in the context of MK2/3 signaling

  • Useful as a comparative stimulus to distinguish pathway-specific effects

• Mechanical stress (relevant to cardiac cells):

  • Induces SRF phosphorylation through mechanotransduction pathways

  • In cardiac myocytes, mechanical stretch can trigger RSK3-mediated SRF phosphorylation

  • Time course and magnitude may differ from chemical stressors

Understanding these stimulus-specific phosphorylation patterns is essential for designing experiments that accurately model physiological stress responses.

What role does the phospho-SRF cistrome play in determining cell type-specific responses?

The phospho-SRF cistrome exhibits cell type-specific patterns that contribute to specialized transcriptional responses:

• Cardiac myocyte-specific features:

  • In ventricular myocytes, phospho-SRF associates with enhancers controlling genes involved in concentric hypertrophy

  • The balance between phosphorylated and non-phosphorylated SRF determines the direction of myocyte growth (width vs. length)

  • Cardiac-specific cofactors may interact preferentially with phospho-SRF

• Cell type-specific cofactor interactions:

  • Phospho-SRF may interact with different sets of transcription factors depending on cell type

  • In some contexts, phosphorylation may enhance interaction with AP-1 factors

  • Tissue-specific expression of signalosome components (like mAKAPβ in cardiac tissue) shapes phospho-SRF patterns

• Integration with epigenetic landscape:

  • Cell type-specific chromatin accessibility affects phospho-SRF binding patterns

  • Enhancer-promoter interactions regulated by phospho-SRF may be cell type-dependent

  • Developmental programming may establish cell type-specific phospho-SRF responses

• Implications for therapeutic targeting:

  • Cell type-specific phospho-SRF cistromes suggest potential for targeted interventions

  • Understanding tissue-specific patterns may help predict off-target effects

  • Therapeutic strategies might focus on disrupting specific phospho-SRF interactions rather than global inhibition